Affiliate files Form 144 showing multiple common stock sales

Affiliate reported proposed sales of Common Stock under Rule 144.

Rhea-AI Filing Summary

Affiliate reported proposed sales of Common Stock under Rule 144. The filing lists multiple entries by Baker Brothers Life Sciences, L.P. showing reported sale activity on 02/24/2026, 02/25/2026, 03/04/2026, and 03/06/2026 with associated numeric entries in the filing. The record also lists Jefferies LLC as an underwriter reference and an earlier underwriting date of 09/22/2020.

Key Figures

Sale entry 02/24/2026: 322,039 shares; $1,944,922.00 Sale entry 02/25/2026: 947,479 shares; $5,501,316.00 Sale entry 03/04/2026: 424,125 shares; $2,654,641.00 +2 more

5 metrics

Sale entry 02/24/2026 322,039 shares; $1,944,922.00 Baker Brothers Life Sciences, L.P. sale line dated 02/24/2026

Sale entry 02/25/2026 947,479 shares; $5,501,316.00 Baker Brothers Life Sciences, L.P. sale line dated 02/25/2026

Sale entry 03/04/2026 424,125 shares; $2,654,641.00 Baker Brothers Life Sciences, L.P. sale line dated 03/04/2026

Sale entry 03/06/2026 461,723 shares; $2,701,080.00 Baker Brothers Life Sciences, L.P. sale line dated 03/06/2026

Underwriter reference Jefferies LLC (09/22/2020) Securities/Underwriter section lists Jefferies LLC and date 09/22/2020

Key Terms

Form 144, Underwriter, Common Stock

3 terms

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Underwriter financial

"Common Stock | Jefferies LLC 520 Madison Avenue New York NY 10022"

An underwriter is a financial firm that evaluates, guarantees and helps sell a new security offering—such as a stock or bond—by buying the issue from the issuer and reselling it to investors or organizing the sale. Think of them as a bridge or safety net: they take on the risk, set the price, handle marketing and paperwork, and their work determines how much money a company can raise and how smoothly the offering reaches the market.

Common Stock financial

"144: Securities To Be Sold | Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What sales are reported for TARA in this Form 144?

The filing lists four reported sale entries by Baker Brothers Life Sciences, L.P. on specific dates. It shows entries for 02/24/2026, 02/25/2026, 03/04/2026, and 03/06/2026 with numeric figures beside each date.

How many shares are listed for the 02/25/2026 entry?

The 02/25/2026 line in the filing shows 947,479 (numeric value) adjacent to that date. The filing presents that figure alongside an associated dollar amount on the same line.

What dollar amounts are shown for the reported transactions?

Each sale line pairs a numeric dollar figure with the share count; examples include $1,944,922.00 for 02/24/2026 and $5,501,316.00 for 02/25/2026 as listed in the filing extract.

Who is listed as underwriter or intermediary in the filing?

The filing names Jefferies LLC, 520 Madison Avenue, New York with an underwriting reference and a date of 09/22/2020 shown in the securities section of the extract.

Is the filing limited to Baker Brothers Life Sciences, L.P.?

The visible excerpt lists multiple sale entries attributed to Baker Brothers Life Sciences, L.P.; other parties are not shown in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 08:42 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001363364
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Protara Therapeutics, Inc.
SEC File Number	001-36694
Address of Issuer	345 Park Avenue South Third Floor New York NEW YORK 10010
Phone	646-844-0337
Name of Person for Whose Account the Securities are To Be Sold	Baker Brothers Life Sciences, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Jefferies LLC 520 Madison Avenue New York NY 10022	300176	1605942.00	55060500	04/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/22/2020	See Remark 2	Underwriter			300176	09/24/2020	See Remark 2

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	02/24/2026	322039	1944922.00
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	02/25/2026	947479	5501316.00
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	03/04/2026	424125	2654641.00
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	03/06/2026	461723	2701080.00

144: Remarks and Signature

Remarks	(1) Baker Brothers Life Sciences, L.P. is affiliated with 667, L.P. Baker Bros. Advisors LP is the investment adviser to 667, L.P. and Baker Brothers Life Sciences, L.P. 667, L.P. is filing separately for the sale of 24,802 shares of common stock ("Common Stock") of Protara Therapeutics, Inc. (the "Issuer"), which along with the reported sales in this form by Baker Brothers Life Sciences, L.P. totals 324,978 shares of Common Stock. (2) Common Stock converted from Series 1 Preferred.
Date of Notice	04/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	By: BAKER BROS. ADVISORS LP, mgmt company and IA to Baker Brothers Life Sciences, L.P., /s/ Scott L. Lessing, President
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)